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MANF is an endoplasmic reticulum resident protein that plays a crucial role in attenuating ER stress 
responses. Although MANF is indispensable for the survival and function of mouse beta cells, its 
precise role in human beta cell development and functio  is unknown. Herein, we show that lack of 
MANF in humans results in diabetes due to increased ER stress leading to impaired beta cell function. 
We identified two patients from different families with childhood diabetes and a neurodevelopmental 
disorder associated with homozygous loss-of-functio mutations in the MANF gene. To study the role 
of MANF in human beta cell development and function, we knocked out the MANF gene in human 
embryonic stem cells and differentiated them into pancreatic endocrine cells. Loss of MANF induced 
mild ER stress and impaired insulin processing capaity of beta cells in vitro. Upon implantation to 
immunocompromised mice, the MANF knockout grafts presented elevated ER stress and functional 
failure, particularly in diabetic recipients. By describing a new form of monogenic 
neurodevelopmental diabetes syndrome caused by disturbed ER function, we highlight the importance 
of adequate ER stress regulation for proper human beta cell function and demonstrate the crucial role 
of MANF in this process. 
  
Introduction 
Autosomal recessive causes of childhood-onset monogenic diabetes commonly present with 
syndromic diabetes (diabetes and additional non-autoimmune features). For instance, individuals 
carrying homozygous loss-of-function variants in WFS1, SLC19A2 and SLC29A3 develop diabetes in 
childhood with multiple non-autoimmune additional features (1–3). Autosomal recessive genetic 
diseases are enriched in populations with high rates of consanguinity (4). Genetic studies of children 
with syndromic diabetes who are born to consanguineo s parents facilitates the identification of novel 
recessive causes of syndromic diabetes.  
Recent studies highlight the important role of mesencephalic astrocyte-derived neurotrophic 
factor (MANF) in maintaining normal endoplasmic reticulum (ER) homeostasis (5). The major 
phenotype in juvenile MANF knockout mice is insulin-deficient diabetes, indicating the important role 
of MANF in the beta cell (6). Beta cells are under high demand for insulin synthesis, folding and 
secretion. ER is the intracellular compartment where p oinsulin molecules fold to their native 
conformation before transport to Golgi for further granule packaging and secretion (7). Accumulation 
of unfolded and misfolded proteins in the ER leads to ER stress and activation of the unfolded protein 
response (UPR) (8). If prolonged, unresolved ER stres  leads to cell death which is mainly mediated 
by DNA damage inducible transcript 3 (DDIT3/CHOP) (9). Therefore, any alterations in the 
mechanisms controlling protein folding may have a deleterious effect on beta cell function and survival 
(10). 
In this study, we undertook whole genome sequencing for children with syndromic diabetes, 
aiming to identify novel autosomal recessive loss-of-function mutations (human knockout) causing 
monogenic diabetes. We show that homozygous loss-of-function variants in MANF cause a novel 
multisystem disorder characterised by childhood-onset diabetes, short stature, deafness, developmental 
delay and microcephaly. To study the role of MANF in human beta cell development and to create an 
experimental model for human diabetes caused by loss of MANF, we generated MANF knockout 
human embryonic stem cells (hESC) and differentiated th m into pancreatic islet endocrine cells. Our 
results show that lack of MANF does not affect the development of human beta cells but increases their 
susceptibility to ER stress-induced functional failure. Our experimental findings provide a pathogenic 
explanation for the phenotype of the patients. 
 
Research design and methods 
Patient cohort  
We investigated 32 children with syndromic diabetes with low likelihood of type 1 diabetes from 8 
paediatric diabetes clinics across Turkey, a country with high rates of consanguinity (11). Syndromic 
diabetes was defined as the presence of any non-autimmune features in addition to diabetes. All of 
the children were negative when tested for islet auto ntibodies and their type 1 diabetes genetic risk 
score was <50th centile of type 1 diabetes population (12). Ethical approval for the study was from 
Kocaeli and Dokuz Eylul University ethics committee and Wales Research Ethics Committee. The 
study was conducted in accordance with the Declaration of Helsinki, and all subjects or their parents 
gave informed consent for genetic testing. 
Molecular genetic analysis  
The Molecular genetic analysis plan to identify novel homozygous predicted loss-of-function variant 
causing syndromic diabetes is described in supplementary figure 1.  
We first performed targeted next-generation sequencing for all known monogenic diabetes genes as 
previously described (13). Individuals with likely pathogenic and pathogenic variants according to 
ACMG guideline were excluded (14). We calculated homozygosity from the off target reads of 
targeted next-generation sequencing gene panel using a SavvyHomozygosity tool 
(https://github.com/rdemolgen/SavvySuite) (15). We only took forward patients with calculated 
homozygosity >6.5% to increase the likelihood of identifying a novel homozygous pathogenic variant.  
We performed gene discovery in the remaining eight ndividuals by whole genome sequencing. 
Genome sequencing was performed using BGI-Seg 500 on DNA extracted from peripheral blood 
leukocytes. The mean depth across these eight genomes were 35. The sequencing data were analysed 
using an approach based on the GATK best practice guidelines. GATK haplotype caller was used to 
identify variants which were annotated using Alamut ba ch version 1.11 (Sophia Genetics, Rouen, 
France) and variants which failed the QD2 VCF filter or had less than 5 reads supporting the variant 
allele were excluded. Copy number variants were call d by SavvyCNV which uses read depth to judge 
copy number states (https://github.com/rdemolgen/SavvySuite) (15).  
We prioritized homozygous protein truncating variants (frameshift, nonsense and splice 
acceptor/donor excluding last exon) in these genomes. These variants are predicted to cause loss of 
function by nonsense mediated mRNA decay (16). We inv stigated variants in the genes where there 
are no individuals with homozygous protein truncating variant in population and where homozygous 
protein truncating variants are not known to cause monogenic disease. We used multiple 
genome/exome population databases. This included gnomADv2.1 (n=135,743), gnomADv3 
(n=71,702) (https://gnomad.broadinstitute.org) (17), TOPMed Freeze5 (n=62,784, 
https://bravo.sph.umich.edu/freeze5/hg38/) and two population with higher rates of consanguinity 
(The Greater Middle East (GME) Variome Project, n=2497)(http://igm.ucsd.edu/gme/index.php) (18) 
and Genes & Health, n=8921, Sep 2019 download (19).
Variant confirmation and co-segregation in family me bers were performed by Sanger sequencing 
(primer sequences available in Supplementary Table 1).  
To identify additional patients with a variant in the putative candidate gene we used literature review, 
internet search (20) and Sanger sequencing of the candidate gene in patients selected based on 
homozygosity over the candidate gene and/or similar clinical features as a proband. The patients were 
referred for diagnostic genetic monogenic diabetes testing performed at the Department of Molecular 
Genetics, Royal Devon and Exeter NHS Trust, Exeter, UK and did not have a pathogenic variant in 
the known monogenic diabetes genes. 
qRT-PCR analysis of MANF expression in human blood   
Peripheral blood was collected in PAXgene Blood RNA tubes (PreAnalytix GmbH, Switzerland) and 
RNA extracted using the PAXgene Blood RNA kit (QIAGEN, Germany). Total RNA was DNase-
treated using the TURBO DNA-free kit (Ambion, USA) and reverse transcribed using Superscript IV 
Reverse Transcriptase (Invitrogen, USA). Triplicate qPCR reactions (5µl) using TaqMan Gene 
Expression assays (Applied Biosystems, USA) were caried out on a QuantStudio 12K Flex (Thermo 
Fisher Scientific, USA).  TaqMan Gene Expression assay IDs used are as follows: Hs00180640_m1 
(MANF), Hs01060665_g1 (ACTB), Hs00831112_s1 (RPL11), Hs00984230_m1 (B2M), 
Hs00939627_m1 (GUSB) and Hs02786624_g1 (GAPDH). Expression of MANF was normalized 
using the geometric mean of five housekeeping genes (ACTB, RPL11, B2M, GUSB, GAPDH). 
Cell culture and in vitro differentiation of human embryonic stem cells 
Human embryonic stem cells (hESC) (WA01/H1 line, Wicell) were cultured on Matrigel-coated plates 
(BD Biosciences) in Essential 8 (E8) medium (Life technologies, A1517001). Differentiation was 
carried out following a seven-stage protocol as previously described with further modifications (21–
23). The glucose concentration of each stage was as follow: S1-S4 cells were cultured in 10.5 mM 
glucose; S5-S6 cells were cultured in 20.5 mM glucose; and S7 cells were cultured in 5.5 mM glucose. 
 
Genome editing 
To recapitulate the gene mutations found in the patients, guide RNAs targeting the first exon of MANF 
gene for deletion were designed using Benchling (https://benchling.com). gRNAs with the highest 
quality score and lowest off-targets score were selct d and purchased, alongside the RNP components 
(HiFi Cas9 protein, crRNA and tracrRNA), from Integrated DNA Technologies (IDT) and utilized 
according to the manufacturer’s recommended protocol. Two million undifferentiated stem cells were 
electroporated with the RNP complex using Neon Transfection system (Thermo Fisher, 1100 V, 20ms, 
two pulses), and plated on Matrigel-coated plates in E8 medium containing 10 µM ROCK inhibitor 
overnight. Afterwards, cells were single-cell sorted, xpanded, and screened for the desired deletion 
using PCR. Positive clones were validated by Sanger sequencing and characterized for pluripotency 
and chromosomal integrity.  
Western blot analysis 
To extract whole cell protein from hESC-derived cells, cells were washed with ice-cold PBS and lysed 
with 300 µL Laemmli buffer (Bio-Rad) for 10 min on ice. The cells were then sonicated (3 x 15 s) and 
the homogenate centrifuged at 1000 rcf for 10 min at 4°C, heated at 95°C  for 5 min. Equal amounts 
of supernatant were run on Any kD Mini-PROTEAN TGX gel (Bio-Rad, Hercules, CA, USA) at 100 
V for 1 h in SDS running buffer (Bio-Rad). Proteins were then transferred to a nitrocellulose membrane 
(Invitrogen) using iBlot system (Invitrogen) for 5 min. The membrane was blocked in Tris-buffered 
saline containing 0.05% Tween (TBS-T) and 5% low fat dried milk for 90 min at 4°C. The membrane 
was then probed the primary antibody overnight at 4°C, washed twice with TBS-T, and incubated with 
the corresponding secondary antibody for 1 h at room temperature. Chemiluminescence detection was 
performed following Amersham ECL (Cytiva, RPN2235) exposure using Chemidoc XRS+ system 
and Image Lab Software (BioRad). Details of the used antibodies are listed in supplementary table 2. 
Flow cytometry analysis 
hESC-derived cells were dissociated into single cells by incubation with TrypLE for 7-10 min at 37°C 
and resuspended in cold FBS/PBS (5% v/v). For surface marker staining of CXCR4, 1 million cells 
were incubated with the directly conjugated antibody CD184/CXCR4 APC at a final dilution of 1:10 
for 30 min at room temperature. For intracellular markers, 1 million cells were first fixed in 250 µl of 
Cytofix/Cytoprem Buffer (BD, No. 554722) for 20 min at 4°C, then washed twice with BD Perm/Wash 
Buffer Solution (BD, No. 554723). Cell pellet was resuspended in 80 µl FBS/BD Prem/Wash buffer 
(4% v/v) and incubated with the corresponding directly onjugated antibody at a final dilution of 1:80 
overnight at 4°C. After incubation with the antibody, cells were washed twice and analyzed using 
FACSCalibur cytometer (BD Bioscience) and FlowJo software (Tree Star Inc.). Gating was defined 
using isotype antibodies. Details of the used antibodies are listed in supplementary table 2.  
Quantitative RT-PCR 
Gene expression was assessed at different stages of differentiation. Total RNA was extracted using 
NucleoSpin Plus RNA kit (Macherey-Nagel). Quantificat on and quality of the RNA preparations were 
measured using SimpliNano (General Electric) spectrophotometer. For cDNA synthesis, 1.5 µg RNA 
was first denatured for 1 min at 65°C, then reverse t anscribed (RT) using GoScript™ Reverse 
Transcriptase kit (Promega). cDNA (50 ng) was amplified by qRT-PCR using 5x HOT FIREPol 
EvaGreen qPCR Mix Plus and 5 µL of forward and reverse primer mix at 2 µM each in a final volume 
of 20 µL. The reagents were pipetted by QIAgility (Quiagen) liquid handling system into 100 well 
disc and run in Rotor-Gene Q (Qiagen) thermo-cycler programmed as follows: 95°C for 15 min, 
followed by 40 cycles of 95°C for 25 s; 57°C for 25 s; 72°C for 25 s; and finished by a melting step. 
Rotor-Gene Q software (Qiagen) was used to calculate cycle threshold values (Ct). Cyclophilin G 
(PPIG) was used as an endogenous housekeeping gene to calculate ∆Ct, and normalized to 
undifferentiated hESCs to calculate ∆∆Ct values and relative gene expression. Exogenous psitive 
control was used as a calibrator and RT-reaction without template was used as a negative control. 
Details of the used primers are listed in supplementary table 2. 
Induction of endoplasmic reticulum stress  
Fifty islet-like aggregates were manually picked anincubated in full S7 media supplemented with the 
corresponding concentration of ER-stress inducers. After the treatment, aggregates were collected, 
fixed with 4% PFA for 3 hours at room temperature, embedded in paraffin, and then processed for 
immunohistochemistry. 1 µM of thapsigargin (T9033, Sigma-Aldrich) and 5 µg/mL of tunicamycin 
(T7765, Sigma-Aldrich) were used for 48 hr, while 1 µg/ml of brefeldin A (B5936, Sigma-Aldrich) 
was used for 24 hr. DMSO was used as a vehicle control at 5 µL/mL. 
Immunocytochemistry and histology 
For adherent cultures, cells were fixed in 4% PFA for 15 min at RT, permeabilized with 0.5% triton-
X100 in  PBS, then blocked with UltraV block (ThermoFisher) for 10 min and incubated with primary 
antibodies diluted in 0.1% Tween in PBS overnight at 4°C. After incubation, cells were washed twice 
with PBS and incubated with corresponding secondary antibodies diluted in 0.1% Tween in PBS for 
1 h at room temperature. For islet-like aggregates paraffin embedding, aggregates were fixed in 4% 
PFA for 3 h at RT, briefly stained with Eosin, then mbedded in 2% low-melting agarose (Sigma-
Aldrich) and transferred to paraffin blocks. For grafts, graft-containing kidney was retrieved, fixed in 
4% PFA for 24 h at RT, and processed for paraffin emb dding. Paraffin sections of 5 µm thickness 
were deparaffinised and antigen retrieval was carried out using the Decloaking Chamber (Biocare 
Medical) in citrate buffer at 95 °C for 12 min. Blocking and incubation with antibodies were performed 
as described above. For TUNEL assay, In Situ Cell Death Detection Fluorescein kit (Roche, 
#11684795910) was utilized according to manufacturer’s instruction. Details of the used antibodies 
are listed in supplementary table 3. 
Static glucose stimulated insulin secretion (GSIS) 
Fifty islet-like aggregates were manually picked and pre-incubated in 3.3 mM glucose-containing 
Krebs buffer in a 12-well plate placed on a rotating platform for 90 min at 37°C. Aggregates were then 
washed with Krebs buffer and sequentially incubated in Krebs buffer containing 3.3 mM glucose, 16.6 
mM glucose, and 3.3 mM glucose + 30 mM KCL, for a period of 30 min. Samples of 300 µl were 
collected from the supernatant of each treatment and stored at -80°C for Insulin ELISA measurements. 
After the last incubation, aggregates were collected and lysed in acid ethanol for determination of total 
insulin content and DNA content. Stimulated insulin secretion results are presented as fractional 
release of total human insulin content after cell mass normalization using total DNA content. 
Implantation of SC-islets 
All experiments were approved by the Animal Welfare Committee of Southern Finland 
(ESAVI/14852/2018). NOD-SCID-gamma (NSG) (Jackson Laboratories, 0055577) were maintained 
at Biomedicum Helsinki animal facility, on a 12h light/dark cycle with ad libitum food. Mice were 
anesthesized with isoflurane, and subcutaneously injected with Carprofen (Rimadyl, 5 mg/Kg, Prizer, 
Helsinki, Finland) and Buprenorphine (Temgesic, 0.05 - 0.1 mg/Kg, RB pharmaceuticals Lmt, 
Berkshire, UK) as analgesics. Approximately 500 SC-islets were loaded on a PE-50 tubing and 
transplanted under the kidney capsule as previously described (24). Mouse blood samples were 
collected monthly from the saphenous vein using heparin-coated capillary tubes. Blood plasma was 
separated by centrifugation (5000 rcf, 5 min, RT) and stored at -80°C for human C-peptide analysis. 
Streptozotocin treatment 
After 3 months of implantation, mice were fasted for 4 h, then intraperitoneally injected with 130-150 
mg/Kg streptozotocin (STZ, S0130, Sigma). STZ was solubilized in cold 0.1 M citrate buffer 
composing of 0.1 M citric acid monohydrate and 0.1 M trisodium citrate dehydrate. Drinking water 
was replaced with 10% sucrose-containing tap water for 48 h to avoid hypoglycemia caused by 
unregulated insulin release from dying β-cells. 
Intraperitoneal glucose tolerance test (IPGTT) 
After 6 h of fasting, mice were intraperitoneally injected with 2 g glucose/kg in the form of 30% 
glucose in saline. Blood glucose levels were measured sing a glucometer (OneTouch Ultra, Lifescan, 
Milpitas, USA), and blood samples were collected for measuring human C-peptide levels at 0, 15, 30, 
60, and 90 min after glucose injection. 
ELISA 
Insulin levels were measured from the in vitro samples with the Insulin ELISA kit (Mercodia, Sweden), 
and human-specific C-peptide was measured from plasma samples with Ultrasensetive C-PEPTIDE 
ELISA kit (Mercodia, Sweden). 
Image acquisition and analysis 
For adherent cultures, Evos inverted microscope (Lif -Technologies) was used to image the cells. For 
paraffin sections, Zeiss Axio Observer Z1 with Apotome was used to image the cells, then images 
were processed with ZEN2 software. All paraffin sections were equally treated and imaged with the 
same microscope parameters. Image quantification were p rformed using CellProfiler software (25) 
and FIJI software (26). 
Statistical analysis 
All data are presented as individual points with their mean ± SEM. Statistical significance evaluation 
was conducted by unpaired, two-tailed Student t test with Welch’s correction using GraphPad Prism 8 
software (GraphPad Software, La Jolla, CA). P-values nder 0.05 were considered statistically 
significant and displayed as *, P-values under 0.001 were presented as **, and P-values under 0.0001 
were presented as ***. 
Data and resource availability  
The data generated and analyzed during this study are included in the published article and its online 




Identification of individuals with homozygous protein truncating variants in MANF 
We performed gene discovery by whole genome sequencing on 8 subjects with non-autoimmune 
diabetes and additional extra-pancreatic features to identify novel homozygous loss of function cause 
of syndromic diabetes. The subjects did not have mutation in any of the known monogenic diabetes 
genes and had high genome wide homozygosity (>6.5%) (Supplementary figure 1A). Analysis of 
genome sequencing data identified one individual (case 1) with a novel homozygous frameshift variant 
in MANF (Chr3(GRCh37):g.51422846_51422858del, NM_006010.5:c.82_94del, p.Leu28Thrfs*33) 
(Fig 1) (Supplementary figure 1B). The variant was not present in 5 large independent population 
exome/genome databases (combined total n=281647) (17). None of these population databases had 
any homozygous protein truncating or rare homozygous missense (MAF <0.01) variants suggesting 
rare homozygous variants in MANF are highly intolerant to human.  
Replication analysis identified a second independent individual (case 2) with a different homozygous 
protein truncating variant in MANF (NM_006010.5:c.103+1G>T, essential donor splice sit ). This 
case was partially described by Yavarna et al. (27).  Case 2 was part of the exome study of individuals 
with clinically suspected mendelian disease (27). Similar to case 1, this variant is not seen in any 
population databases. The parents of both cases were heterozygous for MANF variants. Sanger 
sequencing of MANF from additional 187 patients presenting with diabetes, and microcephaly or 
developmental delay or deafness or short stature and/or homozygous for the region incorporating 
MANF, did not identify additional cases. 
Both protein truncating variants are in exon 1. They g nerate premature termination codons and are 
predicted to cause loss of MANF due to classical nonsense-mediated mRNA decay of the mutant 
mRNA pathway (28). In line with this, MANF mRNA in peripheral blood of the case 1 was 5 fold 
lower compared to control individuals without damaging MANF variants (p=0.02) (Supplementary 
figure 2). These data suggest that both of these cas s re lacking MANF and likely to represent a human 
knockout of MANF. 
Lack of MANF causes diabetes, deafness, developmental delay, microcephaly and short stature. 
Both case 1 and case 2 present a similar clinical phenotype of childhood onset diabetes, short 
stature (<-3SD), bilateral sensorineural deafness, microcephaly and developmental delay (Fig. 1, 
Supplementary table 2). The diabetes was diagnosed at 10 and 17 years, respectively. Case 1 had brief 
treatment (10 days) with insulin followed by diet control diabetes for 1.5 y. Both patients are currently 
on insulin. They did not have autoantibodies associated with type 1 diabetes and have persistence of 
endogenous insulin secretion for ≥4 years post diagnosis, with C-peptide levels of 240 pmol/l and 330 
pmol/l, respectively. Case 2 also has partial hypopituitarism with deficiency in growth hormone, 
thyroid stimulating hormone and gonadotropins. Hypopituitarism has not been detected in case 1 by 
14y of age. Father of case 1 has a BMI of 29.4 and was diagnosed with type 2 diabetes at age 33. He 
is currently 41 and being treated with metformin. He does not present any other features as case 1.   
Generation of a MANF knockout stem cell model 
The homozygous mutations in both cases were found in exon 1 of the MANF gene (Fig. 1A and 
1B). Therefore, we created an experimental model for dissecting the role of MANF in human beta cell 
development and function using CRISPR-Cas9 mediated genome editing to generate a deletion 
encompassing the first exon of MANF gene in H1 hESC. The genomic DNA sequencing of the 
generated clone showed the successful deletion of the targeted sequence which resulted in complete 
absence of MANF protein as shown by western blot analysis (Fig. 1C, Supplementary Fig. 2A). The 
generated clone was karyotypically normal and expressed markers of pluripotency (Supplementary 
Fig. 2B, 2C, and 2D). The KO clone, alongside its wild type counterpart, was differentiated into 
pancreatic islets for further studies. 
MANF knockout stem cells differentiate normally to beta cells 
To study the role of MANF in pancreatic development, we differentiated MANF-KO H1 (H1-
MANF-KO) and wild type H1 hESC into pancreatic islet  following an optimized stepwise 
differentiation protocol (Fig. 2A). Both cell lines differentiated with similar efficiencies into definitive 
endoderm lineage, where approximately 95% of the cells expressed the definitive endoderm cell 
surface marker CXCR4 (Fig. 2B, Supplementary Fig. 3A) (29). After 12 days of differentiation (at S4, 
pancreatic progenitor stage), both cell lines were similarly co-expressing the pancreatic progenitor 
markers PDX1 and NKX6-1 in approximately 60% of thecells (Fig. 2B, Supplementary. Fig. 3A). 
This was further confirmed by their similar levels of PDX1 and NKX6-1 mRNA expression (Fig. 2C). 
Immunocytochemistry analysis at this stage showed similar expression pattern of pancreatic progenitor 
and endocrine markers in both cell lines (Fig. 2D). At the end stage (S7 SC-islets, islet endocrine cells), 
both cell lines generated approximately 35% insulin producing cells (Fig. 2B, Supplementary. Fig. 
3A), and similar mRNA transcript levels of INS, GCG, and MAFA, a marker of mature beta cells (Fig. 
2C) (22). Quantitative immunocytochemistry of these st m cell-derived islets (SC-islets) showed a 
similar ratio of monohormonal cells (INS+ and GCG+) (Fig. 2D and 2E). Taken together, these data 
indicate that MANF deficiency does not alter the differentiation of human pluripotent stem cells into 
pancreatic beta cells in vitro. 
MANF knockout sensitizes beta cells to ER stress 
To assess the effect of MANF-KO on the expression levels of ER stress markers we employed 
immunocytochemistry on S7 SC-islets. MANF-KO beta-like cells showed marginally higher levels of 
BiP when compared to WT (Fig. 3A and B). This might indicate a higher level of ER stress in the 
MANF-KO beta-like cells, which could be associated with the higher accumulation of proinsulin in 
these cells (Fig. 3A and B). Interestingly, MANF-KO cells displayed significantly higher number of 
KI67+ proliferative beta-like cells when compared to the wild type (Fig. 3A and B). Furthermore, we 
confirmed our findings by quantifying the mRNA levels of ER stress markers using RT-qPCR, which 
showed an increasing trend in the expression levels of BiP (HSPA5), GRP170 (HYOU1), and TXNIP 
in MANF-KO cells (Fig. 3C, Supplementary Fig. 3B). However, both genotypes showed similar very 
low basal mRNA transcript levels of the inflammatory markers TNFα, CXCL-10, IL-6, and IFNα (data 
not shown). 
To evaluate the role of MANF in beta cell survival, we quantified apoptotic cells using the 
TUNEL assay on S7 SC-islets treated with different ER stressors. In the basal condition, approximately 
1.5% of the insulin positive cells were TUNEL+ in both MANF-KO and WT (Fig. 3D). Upon the 
induction of experimental ER stress using tunicamycin (TM), an inhibitor of N-linked glycosylation, 
or thapsigargin (TG), which depletes ER calcium (30), the percentage of apoptotic beta-like cells 
increased similarly in both genotypes (~ 8% with TM, and 5% with TG). However, upon the treatment 
with brefeldin A, an inhibitor of ER-to-Golgi cargo transfer (31), the percentage of MANF-KO 
apoptotic beta-like cells was significantly higher than WT (29% vs. 18%) (Fig. 3D, Supplementary 
Fig. 3C). These findings suggest that depletion of MANF results in mildly increased levels of ER stress 
in stem cell-derived beta cells in vitro, making them more sensitive to additional ER stress. 
Impaired insulin processing in MANF knockout beta cells 
Next, we examined the functionality of the SC-islet by performing static insulin secretion tests. 
Both genotypes responded to high glucose with a two-fold increase in human insulin secretion (Fig. 
3E, Supplementary. Fig. 3D). Additionally, KCl induced a four-fold increase of insulin release in both 
genotypes, indicating normal insulin secretion respon e to depolarization (Fig 3E). Although both 
genotypes showed a similar pattern of insulin secretion, the absolute amount of insulin secreted by the 
MANF-KO SC-islets was lower and their insulin content was significantly lower than in wild type 
(Fig. 3F). Additionally, MANF-KO cells showed a significantly higher ratio of proinsulin to insulin 
content (Fig 3G) even though proinsulin content wassimilar (Supplementary Fig. 3E). Thus, MANF-
KO had a minor effect on beta cell function but a significant effect on the insulin processing capacity 
of the beta cells in vitro.  
Impaired function of MANF knockout beta cells after implantation 
To evaluate the functionality of SC-islets in vivo, we implanted MANF-KO and WT SC-islets 
under the kidney capsule of immunocompromised (NSG) mice. We followed the functionality of the 
grafted cells for 6 months by measuring the circulating glucose and human C-peptide levels (Fig. 4A). 
Blood glucose levels of the mice implanted with both MANF-KO and WT cells decreased over time 
from usual normoglycemic levels for mice (8 mM) to human levels (4 mM) by 3 months, suggesting 
that the grafted cells were able to efficiently contr l the blood glucose of transplanted mice (Fig. 4B). 
This was consistent with a gradual increase in the lev ls of circulating human C-peptide in randomly 
fed mice, reaching up to 2800 pM after 3 months (Fig. 4C). At 4 months post-implantation, the levels 
of C-peptide in fasted mice were significantly higher in mice implanted with WT cells compared to 
MANF-KO (Fig. 4C). 
Four months after implantation, the mice were challenged with an intraperitoneal glucose 
tolerance test. Blood glucose excursions were significa tly higher in mice transplanted with MANF-
KO grafts (Fig. 4 E and I). This was associated with lower secretion of human C-peptide (Fig. 4F and 
4J). The glucose tolerance test was repeated after eradication of mouse beta cells using a single high
dose of streptozotocin (STZ). The mice carrying WT grafts maintained normal glucose tolerance and 
high human C-peptide secretion in this test. However, the mice transplanted with MANF-KO grafts 
showed reduced glucose clearance (Fig. 4G and 4I) and a substantially lower increase in human C-
peptide secretion (area under the curve, AUC, p= 0.02) (Fig. 4H and 4J). To confirm the functionality 
of the grafts and the success of the STZ treatment in eradicating the mouse beta cells, grafts were 
retrieved after 6 months by unilateral nephrectomy, which resulted in immediate hyperglycemia in all 
mice (Fig. 4D). Taken together, these data show impa red functionality of implanted MANF-KO beta 
cells. 
  
Elevated ER stress and proinsulin accumulation in MANF knockout grafts 
To further evaluate the effect of MANF-KO on the implanted SC-islets, grafts were retrieved at 
1, 2, 4, and 6 months and examined by immunohistochemistry. Staining for INS and GCG in 6 months 
old grafts showed no differences in the proportions f beta and alpha cells between the genotypes, 
further indicating that MANF depletion did not affect pancreatic endocrine differentiation (Figure 5A 
and B). The percentage of INS+ cells in the grafts increased gradually with time (Supplementary Fig. 
4E), while the number of proliferating beta cells gradually decreased (Supplementary. Fig. 4C and 
4D). Interestingly, MANF-KO beta cells showed significantly higher levels of proinsulin (50% 
PROINSHI+INS+/INS+) compared to their wild type counterparts (35% PROINSHI+INS+/INS+) in the 
6-month-old grafts (Fig 5C and D). A similar pattern was observed in the grafts retrieved at 2, and 4 
months, suggesting an important defect in proinsuli processing in the ER (Supplementary Fig. 4G). 
In addition, immunohistochemistry analysis for ER stre s markers in 6-month grafts revealed 
significantly higher levels of the ER stress markers BiP (Fig 5E, 5F, Supplementary Fig. 4H) and 
GRP170 (Supplementary Fig 4A and 4B) in MANF-KO grafts compared to the wild type grafts (23.3% 
vs. 15.4% BiPHI+INS+/INS+ cells and 27.9% vs. 10.2% GRP170HI+INS+/INS+ cells. Finally, TUNEL 
assay for apoptotic INS+ cells revealed an absence of beta cell death in the grafts of both genotypes 
(Supplementary Fig. 4F). 
Discussion 
In this study we report MANF homozygous loss-of-function mutations as a novel genetic cause 
of childhood onset diabetes, deafness, developmental del y, microcephaly and short stature. We 
employed differentiation of hESCs lacking MANF to the pancreatic islets to model the consequences 
of these genetic defects. This revealed the crucial role of MANF in mitigating beta cell ER stress, and 
how its absence leads to impaired proinsulin processing and impaired beta cell function. 
Strong genetic, clinical and functional data suggest that lack of MANF is indeed the cause of 
diabetes in these patients.  The childhood progressiv  diabetes is unlikely to be type 1 diabetes as they
lacked islet autoantibodies, had low genetic risk of type 1 diabetes and significant residual C-peptide 
4 years after diagnosis (32). Both patients with different homozygous mutations have strikingly similar 
extra pancreatic phenotypes with microcephaly, developmental delay, sensorineural deafness and short 
stature. The brain is sensitive to ER stress mediat damage and almost always affected along with 
pancreas in other ER stress mediated monogenic diabetes forms (33). This strongly suggests that 
MANF deficiency is aetiological also for these features.  
Both global and beta-cell specific loss of MANF results in severe early onset diabetes in 
transgenic mice (6,34). The two patients identified in this study were diagnosed with diabetes at the 
age of 10 and 17 years, suggesting a slower progression of the beta-cell failure in humans. In our 
MANF-KO hESC model, obvious signs of severe ER stres  and functional deterioration were only 
evident in the in vivo model when the stem-cell derived beta cells became responsible for the insulin 
secretion of the diabetic host, suggesting again tht loss of MANF leads to progressively impaired beta 
cell function and diabetes.  
MANF-KO mice present neurological phenotypes that resemble those in the human MANF-KO 
patients. MANF inactivation in the mouse inner ear l ds to a progressive death of outer hair cells of 
the cochlea accompanied with hearing loss (35). Similarly to the patients, MANF-KO mice show a 
growth defect and short stature that is independent of diabetes (6).  
The ER stress response is a crucial adaptive pathway for beta cell function and survival. ER 
stress can be triggered by the accumulation of misfolded protein that is unable to exit the ER, as in the 
case of the dominant INS mutations causing severe forms of diabetes in Akita mice and humans 
(23,36). Pathogenic mutations in genes involved in the UPR also lead to neonatal diabetes, as in the 
case of EIF2AK3 mutations in Wolcott-Rallison syndrome (37), IER3IP1 mutations (38) or YIPF5 
mutations (39). Childhood onset diabetes has been dscribed in individuals carrying WFS1 and CISD2 
mutations, leading to Wolfram syndrome (1), and recessive mutations in the DNAJC3 (40) and 
PPP1R15B genes (41). Indeed, the MANF syndrome clinical features of diabetes, microcephaly and 
other neurological features are overlapping with those seen in patients with above mutations (33,42). 
Thus, homozygous MANF mutations constitute a novel form of childhood onset diabetes caused by 
dysregulated ER stress and therefore MANF should be included in the gene panels testing for 
monogenic diabetes. 
Similar to Wolfram syndrome, the MANF syndrome has childhood-onset diabetes with 
progressive beta cell dysfunction, developmental del y, and deafness. However, it lacks optic atrophy, 
diabetes insipidus, and urological defects which are common in Wolfram syndrome. Furthermore, the 
short stature and microcephaly seen in MANF syndrome are not reported in Wolfram syndrome. The 
difference in the clinical features indicates some differences in the pathogenesis. Further work with 
additional patients and animal models will be needed to fully understand these differences. 
High expression of ER-stress markers in human adult beta cells has been linked to higher 
tendency of proliferation (43). Additionally, induction of mild ER stress by hyperglycemia has been 
reported to induce beta cell proliferation (44,45). Conversely, sub-threshold chronic ER stress has been
shown to inhibit the proliferation of beta cells (46). We observed a similar pattern in our model where 
the in vitro mild ER stress significantly induced the proliferation of MANF-KO beta cells, while after 
implantation and exposure to more severe ER stress, there was a trend of decreased proliferation 
(Figure 3, Supplementary Fig. 4D).  
As a compensatory response to ER stress, UPR tends to attenuate protein translation to decrease 
the folding load on the ER (8). This may result in decreased insulin synthesis and processing capacity 
in ER-stressed beta cells. A previous study on Wolfram syndrome, which is caused by ER dysfunction 
(47), reported that although the low levels of UPR signaling decreased the insulin content of beta cells, 
it did not alter their glucose stimulated insulin secretion in vitro (48). These results are well in line 
with the findings of our study, since we can detect a lower level of insulin content and secretion in the
MANF-KO beta cells compared to wild type cells, while the insulin response to glucose stimulation 
was preserved. Additionally, the significantly higher ratio of proinsulin to insulin content in the 
MANF-KO cells, observed both in vitro and in vivo, indicates impaired insulin processing capacity, 
also reported in human prediabetes (49,50) 
In conclusion, our findings indicate the essential role of MANF in protecting beta cells from ER 
stress-induced failure and apoptosis in humans. Our study also highlights the potential of the modelling 
platform which enables detailed studies of isogenic stem-cell derived beta cells both in vitro and in 
vivo. The mild phenotype observed in vitro, representing an immature beta cell population, followed 
by an exacerbated phenotype in more actively functio ing beta cells in vivo, is likely to recapitulate 
the pathogenic evolution of the diabetic phenotype in the patients with MANF mutation. 
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Figure 1: Identification of homozygous MANF mutation in two patients with childhood diabetes. 
A. Pedigrees of the two cases with homozygous MANF variants. Square symbolizes male and circle symbolizes 
female. Black shaded area indicates the presence of diabetes, Blue, and red area indicate the presence of 
short stature and deafness respectively whereas the grey shaded area indicates the presence of microcephaly 
and developmental delay. 
B. Schematic presentation of the MANF gene knockout strategy utilizing CRISPR/Cas9. The positions of 
patient mutations are marked with red arrows, and the used guides to delete exon 1 are presented as blue 
arrow heads. 
C. Representative immunoblot showing the absence of the MANF protein in the generated clone. α-tubulin 
used as a loading control.  
Figure 2: MANF knockout hESC differentiate normally to beta cells 
A. Schematic presentation of the seven-stage differentiation protocol (for further details, see research design 
and methods). 
B. Graphical presentation of flow cytometry analysis of the differentiating hESC for specific relevant markers 
of each stage in H1 (wild type) and H1-MANF-KO (N=8 for S1 and S7 cells; N=7 For S4 cells). For the 
definitive endoderm stage, CXCR4 was used as a surface marker; PDX1 and NKX6-1 double positive 
staining was used as a marker of the pancreatic progenitor population (S4); while NKX6-1 and INS double 
positive staining was used as a marker of end stage β-lik  cells (S7). 
C. Relative gene expression levels of pancreatic genes a alyzed by RT-qPCR in H1 and H1-MANF-KO (N=4 
- 9). 
D. Immunocytochemistry analysis of S4 monolayer cells for PDX1, NKX6-1, chromogranin A (CHGA), and 
insulin (Scale bar=100 µm); and S7 aggregates for insulin, glucagon, and the nuclear stain Hochest (N=6, 
scale bar=100 µm). 
E. Quantification of the percentage of insulin positive- and glucagon positive cells in H1 and H1-MANF-KO 
SC-islets. 
H1 is presented as blue circles and H1-MANF-KO is presented as red circles. Data is presented as mean ± 
SEM 
Figure 3: MANF knockout Beta cells tend to have induced ER stress and significantly reduced insulin 
processing capacity 
A. Immunocytochemistry analysis of H1 and H1-MANF-KO S7 aggregates for β-like cells (INS+) which 
express ER stress marker BiP (N=5), proinsulin (PROINS) (N=6), and proliferation marker (Ki67) (N=8). 
(Scale bar=20 µM) 
B. Quantified relative amounts of BiP, proinsulin and Ki67 positive beta cells from (A). 
C. Relative gene expression levels of ER stress genes analyzed by RT-qPCR in H1 and H1-MANF-KO (N= 4 
- 9). 
D. ER stress-induced apoptosis of S7 aggregates. Quantific tion of the percentage of insulin positive cell which 
are labeled by TUNEL assay after treating the aggregates with the following chemical ER stress inducers: 
tunicamycin (TM), thapsigargin (TG) (N=3), and Brefaldin A (BREF) (N=5). DMSO was used as a vehicle 
control. 
E. Static glucose stimulated insulin secretion of S7 SC-islets. Values are presented as fractional secretion of 
human insulin over total insulin content. (N=6) 
F. Human insulin content of S7 SC-islets. Cell mass is normalized by average DNA content of each aggregate. 
(N=6) 
G. Ratio of human proinsulin content to human insulin content per aggregate. (N=4 for H1, and 3 for H1-
MANF-KO). 
H1 is presented as blue circles and H1-MANF-KO is presented as red circles. Data is presented as mean ± 
SEM. P-values under 0.05 are displayed as *, and P-values under 0.0001 are displayed as ***. 
Figure 4: Impaired response to glucose of MANF knockout cells in vivo 
A. Schematic presentation of the in vivo workflow. 
B. Monthly follow-up of H1 and H1-MANF-KO in vivo functionality by measuring the blood glucose levels 
of implanted mice. Measurements of the first three months were done on randomly fed mice; while for the 
last month, mice were fasted. (N= 11 for H1 and 14 for H1-MANF-KO) 
C. Monthly follow-up of H1 and H1-MANF-KO in vivo functionality by measuring the circulating human C-
peptide levels of implanted mice. Measurements were done on randomly fed mice for the first three months; 
while for the last month, mice were fasted. (STZ). (N= 11 for H1 and 14 for H1-MANF-KO) 
D. Blood glucose measurements before and after removing the implanted kidney of STZ-induced diabetic mice 
by surgical unilateral nephrectomy. (N=7) 
E. Blood glucose measurements during an intraperitoneal glucose tolerance test of fasted H1 and H1-MANF-
KO implanted mice before STZ treatment. (N= 11 for H1 and 14 for H1-MANF-KO) 
F. Levels of circulating human C-peptide during an intraperitoneal glucose tolerance test of fasted H1 and H1-
MANF-KO implanted mice before STZ treatment. (N= 11 for H1 and 14 for H1-MANF-KO) 
G. Blood glucose measurements during an intraperitoneal glucose tolerance test of fasted H1 and H1-MANF-
KO implanted mice after treatment. (N= 6 for H1 and 11 for H1-MANF-KO) 
H. Levels of circulating human C-peptide during an intraperitoneal glucose tolerance test of fasted H1 and H1-
MANF-KO implanted mice after STZ treatment. (N= 6 for H1 and 11 for H1-MANF-KO) 
I. Quantification of the efficiency of the implanted grafts to regulate the mice blood glucose during IPGTT by 
measuring the area under the curve of (E and G).  
J. Quantification of the ability of the implanted grafts to secrete human C-peptide by measuring the area under 
the curve of (F and H). 
H1 is presented as blue circles and H1-MANF-KO is presented as red circles. Data is presented as mean ± 
SEM. P-values under 0.05 are displayed as *, and P-values under 0.001 are displayed as **. 
Figure 5: Increased ER stress and accumulation of PROINS in MANF knockout grafts 
A. Immunohistochemistry analysis of 6 months old grafts for insulin (INS) and glucagon (GCG). Scale bar=50 
µM. 
B. Quantification of the percentage of insulin and glucagon positive cells from (A) (N= 6 for H1 and 9 for H1-
MANF-KO) 
C. Immunohistochemistry analysis of 6 months old grafts for insulin (INS) and proinsulin (PROINS). Scale 
bar=50 µM. 
D. Quantification of the relative number of insulin and proinsulin positive cells from (C) (N= 6 for H1 and 9 
for H1-MANF-KO) 
E. Immunohistochemistry analysis of 6 months old grafts for insulin (INS) cells which are expressing the ER 
stress marker BiP. Scale bar=50 µM. 
F. Quantification of the relative number of BiP positive beta cells from (E) (N= 6 for H1 and 4 for H1-MANF-
KO) 
H1 is presented as blue circles and H1-MANF-KO is presented as red circles. Data is presented as mean ± 
SEM. P-values under 0.05 are displayed as *, and P-values under 0.001 are displayed as **. 
 
